{'fraction_non_alphanumeric': 0.017391304347826087, 'fraction_numerical': 0.007729468599033816, 'mean_word_length': 4.954022988505747, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Migraine prophylaxis 2019 - the role of CGRP antagonists].

Migraine prophylaxis 2019 - the role of CGRP antagonists Abstract. The CGRP System is part of the pain pathway within the complex pathophysiology of migraine. Monoclonal antibodies targeting the CGRP system are the first class of substances developed specifically for the prevention of migraine, i. e. the reduction of attack frequency and intensity. The efficacy of this class of substances is comparable to established anti-migraine prophylactic medication. Tolerability and safety seem excellent in the published studies as well as in our clinical experience up to now. Limitations for reimbursement are expected for all substances within this class due to a relatively high price as compared to established drugs. The first substance in class is on the market in Switzerland. The role, these substances will play in the stratified treatment of sufferers will have to be established in clinical practice after several of these monoclonal antibodies will be on the market.